EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and Cardiovascular Safety of Pegmolesatide in Patients with Anemia of Chronic Kidney Disease: Post hoc Analysis of Two Phase 3 Randomized Trials

Zhiming Ye, Ping Zhang, Zhizhen Hu, Xue Cheng, Ping Li, Weili Luo, Jianghua Chen, Xueqing Yu

Kidney Diseases · 18.06.2026 · 12 (1) · 711-721

DOI: 10.1159/000551808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney Diseases, online erschienen am 18.06.2026. Verfasst von Zhiming Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Chi…. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pegmolesatide selectively binds to the erythropoietin receptor homodimer with higher binding stability and prolonged residency than erythropoietin, potentially offering an improved therapeutic profile for anemia management in chronic kidney disease (CKD) patients. This post hoc analysis of two randomized phase 3 trials compared pegmolesatide with epoetin alfa to further evaluate pegmolesatide’s potential benefits.

Methods

This analysis included a total of 545 patients: 372 with dialysis-dependent (DD)-CKD (248 pegmolesatide, 124 epoetin alfa) and 173 with non-dialysis-dependent (NDD)-CKD (115 pegmolesatide, 58 epoetin alfa). The proportion of patients maintaining mean hemoglobin (Hb) levels ≥10 g/dL and intraindividual hemoglobin variability (Hb-Var) were analyzed. Cardiovascular (CV) safety was assessed using five-point major adverse cardiovascular events (MACE), expanded CV events, and three-point MACE.

Results

During the efficacy evaluation period (weeks 17–24), pegmolesatide showed numerically higher proportions of patients who maintained mean Hb levels ≥10 g/dL versus epoetin alfa in both DD-CKD {91.8% vs. 88.6%; difference: 7.1% (95% confidence interval [CI]: 0.1, 14.2); p = 0.2802} and NDD-CKD (87.0% vs. 85.4%; difference: 3.3% [95% CI: −8.1, 14.6]; p = 0.6091) patients. From the efficacy evaluation period to the extended period (weeks 17–52), patients receiving pegmolesatide exhibited lower Hb-Var compared with those receiving epoetin alfa as measured by within-patient residual standard deviation (DD-CKD: 0.678 g/dL vs. 0.730 g/dL, p = 0.0061; NDD-CKD: 0.647 g/dL vs. 0.677 g/dL, p = 0.3158). The incidences of five-point MACE (DD-CKD: 3.7% vs. 6.5%, hazard ratio [HR] = 0.54 [95% CI: 0.21, 1.39]; NDD-CKD: 0.9% vs. 6.9%, HR = 0.14 [95% CI: 0.02, 1.28]), expanded CV events (DD-CKD: 9.8% vs. 11.3%, HR = 0.83 [95% CI: 0.43, 1.61]; NDD-CKD: 5.2% vs. 12.1%, HR = 0.49 [95% CI: 0.16, 1.45]) and three-point MACE (DD-CKD: 2.0% vs. 3.2%, HR = 0.60 [95% CI: 0.16, 2.23]; NDD-CKD: 0 vs. 1.7%, HR not estimable) were consistently lower in the pegmolesatide group across both patient populations.

Conclusion

Pegmolesatide showed effectiveness in Hb management for both NDD-CKD and DD-CKD populations, with overall numerically favorable CV safety outcomes compared to epoetin alfa.

Schlagwörter

Stichwörter der Autor:innen

AnemiaChronic kidney diseaseEpoetin alfaPegmolesatide

Autor:innen und Institutionen

  • Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Kidney Disease Center, The First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou, China.
  • Hansoh Pharmaceutical Group Co, Ltd, Shanghai, China.

Zitieren

APA

Ye, Z., Zhang, P., Hu, Z., Cheng, X., Li, P., Luo, W., Chen, J., & Yu, X. (2026). Efficacy and Cardiovascular Safety of Pegmolesatide in Patients with Anemia of Chronic Kidney Disease: Post hoc Analysis of Two Phase 3 Randomized Trials. Kidney Diseases, 12(1), 711-721. https://doi.org/10.1159/000551808

Vancouver

Ye Z, Zhang P, Hu Z, Cheng X, Li P, Luo W, et al. Efficacy and Cardiovascular Safety of Pegmolesatide in Patients with Anemia of Chronic Kidney Disease: Post hoc Analysis of Two Phase 3 Randomized Trials. Kidney Diseases. 2026;12(1):711-721. doi:10.1159/000551808

BibTeX
@article{Ye2026,
  author = {Ye, Zhiming and Zhang, Ping and Hu, Zhizhen and Cheng, Xue and Li, Ping and Luo, Weili and Chen, Jianghua and Yu, Xueqing},
  title = {Efficacy and Cardiovascular Safety of Pegmolesatide in Patients with Anemia of Chronic Kidney Disease: Post hoc Analysis of Two Phase 3 Randomized Trials},
  journal = {Kidney Diseases},
  year = {2026},
  volume = {12},
  number = {1},
  pages = {711--721},
  doi = {10.1159/000551808}
}
Kostenlos starten →